Differential regulation of serotonin-1A receptor-stimulated [35S]GTPγS binding in the dorsal raphe nucleus by citalopram and escitalopram

European Journal of Pharmacology

Volumn 583, Issue 1, 2008, Pages 103-107

  Rossi, Dania V ^a   Burke, Teresa F ^a   Hensler, Julie G ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

35S GTP S binding; 3H 8 OH DPAT; Citalopram; Escitalopram; Quantitative autoradiography; Serotonin 1A

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; CIANOPRAMINE; CITALOPRAM; ESCITALOPRAM; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PAROXETINE; SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG RECEPTOR BINDING; MALE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; RECEPTOR OCCUPANCY;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); IMIPRAMINE; MALE; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS;

EID: 39649106317     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.01.022     Document Type: Article

References (19)

1. Blier P., and de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15 (1994) 220-226
2. Castro E.M., Diaz A., del Olmo E., and Pazos A. Chronic fluoxetine induces opposite changes in G protein coupling at pre and postsynaptic 5-HT1A receptors in rat brain. Neuropharmacology 44 (2003) 93-101
3. Ceglia I., Acconcia S., Fracasso C., Colovic M., Caccia S., and Invernizzi R.W. Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptors. Br. J. Pharmacol. 142 (2004) 469-478
4. Chaput Y., de Montigny C., and Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 333 (1986) 342-348
5. Cremers T.I., Spoelstra E.N., de Boer P., Bosker F.J., Mork A., den Boer J.A., Westerink B.H., and Wikstrom H.V. Desensitisation of 5-HT autoreceptors upon pharmacokinetically monitored chronic treatment with citalopram. Eur. J. Pharmacol. 397 (2000) 351-357
6. El Mansari M., Sanchez C., Chouvet G., Renaud B., and Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 30 (2005) 1269-1277
7. Gould G.G., Altamirano A.V., Javors M.A., and Frazer A. A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biol. Psychiatry 59 (2006) 408-414
8. Hensler J.G. Differential regulation of 5-HT1A receptor-G protein interactions in brain following chronic antidepressant administration. Neuropsychopharmacology 26 (2002) 565-573
9. Hjorth S., Bengtsson H.J., Kullberg A., Carlzon D., Peilot H., and Auerbach S.B. Serotonin autoreceptor function and antidepressant drug action. J. Psychopharmacol. 14 (2000) 177-185
10. Kovachich G.B., Aronson C.E., Brunswick D.J., and Frazer A. Quantitative autoradiography of serotonin uptake sites in rat brain using [3H]-cyanoimiprimine. Brain Res. 454 (1988) 78-88
11. Kreiss D.S., and Lucki I. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J. Pharmacol. Exp. Ther. 274 (1995) 866-876
12. Le Poul E., Laaris N., Doucet E., Laporte A.M., Hamon M., and Lanfumey L. Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine. Naunyn-Schmiedeberg's Arch. Pharmacol. 352 (1995) 141-148
13. Millan M.J., Gobert A., Lejeune F., Newman-Tancredi A., Rivet J.M., Auclair A., and Peglion J.L. S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J. Pharmacol. Exp. Ther. 298 (2001) 565-580
14. Owens M.J., Knight D.L., and Nemeroff C.B. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol. Psychiatry 50 (2001) 345-350
15. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1998), Academic Press, New York
16. Rossi D.V., Gould G.G., Valdez M., and Hensler J.G. Chronic citalopram treatment fails to alter 5-HT1A receptor-G protein interaction in the dorsal raphe nucleus. Soc. Neurosci. (2005) Program No. 489.14
17. Rossi D.V., Valdez M., Gould G.G., and Hensler J.G. Chronic administration of venlafaxine fails to attenuate 5-HT1A receptor function at the level of receptor-G protein interaction. Int. J. Neuropsychopharmacol. 9 (2006) 393-406
18. Sanchez C. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin. Pharmacol. Toxicol. 99 (2006) 91-95
19. Shen C., Li H., and Meller E. Repeated treatment with antidepressants differentially alters 5-HT1A agonist-stimulated [35S]GTP gamma S binding in rat brain regions. Neuropharmacology 42 (2002) 1031-1038